Transitional cell carcinoma

BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Friday, May 29, 2020 - 12:30pm

SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QEDs oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma (CCA).

Key Points: 
  • SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QEDs oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma (CCA).
  • An analysis of response rates in patients with advanced/unresectable or metastatic urothelial carcinoma based on the amount of prior lines of treatment showed consistent response to infigratinib.
  • All eight patients in the study with upper tract urothelial carcinoma (UTUC) received infigratinib as second-line or later therapy.
  • Moreover, QED Therapeutics operates in a very competitive and rapidly changing environment in which new risks emerge from time to time.

UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer

Friday, May 15, 2020 - 2:00pm

UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 (Jelmyto (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC).

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 (Jelmyto (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC).
  • OLYMPUS (Optimized DeLivery of Mitomycin for Primary UTUC Study) is an open-label, single-arm Phase 3 clinical trial of Jelmyto (mitomycin) for pyelocalyceal solution to evaluate the safety, tolerability and tumor ablative effect of Jelmyto in patients with low-grade upper tract urothelial cancer.
  • Jelmyto (mitomycin) for pyelocalyceal solution is a drug formulation of mitomycin for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO

Wednesday, May 13, 2020 - 10:00pm

By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the bodys immune response.

Key Points: 
  • By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the bodys immune response.
  • Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell antitumor activity.
  • Tecentriq is a prescription medicine used to treat adults with:
    A type of bladder and urinary tract cancer called urothelial carcinoma.
  • The approval of Tecentriq in these patients is based on a study that measured response rate and duration of response.

Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types

Wednesday, May 13, 2020 - 10:00pm

Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX) and atezolizumab (TECENTRIQ) in patients with locally advanced or metastatic solid tumors.

Key Points: 
  • Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX) and atezolizumab (TECENTRIQ) in patients with locally advanced or metastatic solid tumors.
  • Fifty percent of patients received the cabozantinib and atezolizumab combination as their second line of therapy and 50% as their third line of therapy.
  • Further evaluation of cabozantinib and atezolizumab in patients with advanced tumor types, including immune checkpoint inhibitor-pretreated NSCLC, and forms of prostate and urothelial cancers, is warranted.
  • The efficacy data and favorable safety profiles seen in the three cohorts suggest the combination of cabozantinib and atezolizumab offers promise for patients with advanced, difficult-to-treat tumor types.

New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program

Tuesday, May 12, 2020 - 5:00pm

Pfizer Inc. (NYSE: PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from May 29-May 31.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from May 29-May 31.
  • These data will support our rapidly expanding efforts in bladder cancer and add to the growing body of clinical evidence generated with XTANDI in prostate cancer.
  • Key presentations featuring Pfizer medicines in the ASCO20 Virtual Scientific Program include:
    Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase 3 interim analysis.
  • At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients.

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Locally Advanced or Metastatic Urothelial Carcinoma

Thursday, May 7, 2020 - 11:10pm

Urothelial carcinoma is the most common (more than 90%) histologic type of bladder cancer in China.

Key Points: 
  • Urothelial carcinoma is the most common (more than 90%) histologic type of bladder cancer in China.
  • It ranked ninth for all cancer deaths in China, accounting for about 14% of bladder cancer deaths worldwide.
  • In China, patients with advanced urothelial carcinoma after failure of standard chemotherapy have limited treatment options.
  • Toripalimab received its first approval for 2nd line treatment of metastatic melanoma on December 17, 2018 in China and was commercially launched in February 2019.

UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments

Thursday, May 7, 2020 - 1:00pm

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • On April 15, 2020, the FDA approved Jelmyto, making it the first drug approved for the treatment of LG-UTUC in adult patients.
  • Urothelial cancer is the ninth most common cancer globally and the eighth most lethal neoplasm in men in the U.S.
  • Our primary focus is on the health and well-being of patients, caregivers, and UroGen employees at this critical juncture.

New Data at the ASCO20 Virtual Scientific Program Reflects Genentech’s Commitment to Accelerating Progress in Cancer Care

Thursday, May 7, 2020 - 6:00am

Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.

Key Points: 
  • Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.
  • Tecentriq is a prescription medicine used to treat adults with:
    A type of bladder and urinary tract cancer called urothelial carcinoma.
  • The approval of Tecentriq in these patients is based on a study that measured response rate and duration of response.
  • Continued approval for this use may depend on the results of an ongoing study to confirm benefit.

Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020

Tuesday, May 5, 2020 - 1:00pm

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the BofA Securities Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m. Eastern Time.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the BofA Securities Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m. Eastern Time.
  • The presentation will be webcast live and available for replay from Seattle Genetics website at www.seattlegenetics.com in the Investors section.
  • Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives.
  • ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers.

The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial

Thursday, April 30, 2020 - 1:00pm

In the pivotal OLYMPUS trial, participants received six once-weekly instillations of Jelmyto via retrograde catheter in the renal pelvis and calyces.

Key Points: 
  • In the pivotal OLYMPUS trial, participants received six once-weekly instillations of Jelmyto via retrograde catheter in the renal pelvis and calyces.
  • As reported in The Lancet Oncology publication, in the trial, 67 patients (94%) experienced adverse events (AEs) and 60 patients (85%) had AEs that were considered to be related to the study treatment or procedure.
  • Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): a prospective single-arm phase 3 trial.
  • The Lancet Oncology, 2020
    Browne BM, Stensland KD, Moynihan MJ, Canes D. An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database.